In short. Cutaneous squamous cell carcinoma: the higher-risk features that change management, the transplant-patient question, and what surveillance after treatment involves.
Key points
- People taking immunosuppressant medication after organ transplantation develop squamous cell carcinoma far more often than the general population — often many tumours, often on sun-exposed skin, and with a higher rate of spread.
- The same applies to some other immunosuppressed groups.
- This is not a reason to stop medication, which protects the transplant.
Cutaneous squamous cell carcinoma is the second most common skin cancer and the one where risk is most unevenly distributed. Many tumours are indolent and cured by a straightforward excision. A minority behave aggressively, spread to lymph nodes, and occasionally prove fatal. The clinical task is to identify which is which, because that determines the width of the operation, whether lymph nodes are discussed, and how closely you are followed.
What it looks like
Typically a firm, rough or scaly lump with a crusted or ulcerated surface, often on sun-damaged skin of the face, scalp, ears, neck, hands or forearms. It grows over weeks to months, faster than basal cell carcinoma, and may bleed or become tender. Some arise from a pre-existing actinic keratosis or from Bowen disease; others appear on chronic wounds, burns or scars, where they are easy to overlook.
Higher-risk features
Risk is assessed from the tumour, the patient and the site. Tumour features that raise concern include a diameter above roughly two centimetres, invasion beyond the dermis into subcutaneous fat or deeper, perineural invasion, poor differentiation, and certain aggressive subtypes. Site matters: tumours of the lip, ear and temple have a higher rate of spread, as do those arising in scarred or previously irradiated skin. Patient factors include long-term immunosuppression, a previous squamous cell carcinoma, and inherited conditions that impair DNA repair.
The transplant question
People taking immunosuppressant medication after organ transplantation develop squamous cell carcinoma far more often than the general population — often many tumours, often on sun-exposed skin, and with a higher rate of spread. The same applies to some other immunosuppressed groups. This is not a reason to stop medication, which protects the transplant. It is a reason to be examined regularly, to treat lesions early, and for the skin team and the transplant team to review the immunosuppression together, because adjustments can measurably reduce the rate of new tumours.
Treatment
Surgical excision with an adequate margin and pathological confirmation is the standard for the great majority of tumours; margin-controlled serial excision is used for high-risk sites and aggressive subtypes. Where the tumour carries high-risk features, a discussion about draining lymph nodes — sampling the first node, imaging, or structured observation — is part of planning rather than an afterthought. Radiotherapy has a role for some patients who cannot undergo surgery, or as additional treatment in high-risk disease.
Surveillance
After treatment the priorities are detecting recurrence at the treated site, finding new primary tumours, and watching for nodal spread in higher-risk cases. Review intervals are set by risk: a low-risk tumour on a forearm needs far less attention than an ear tumour in a transplant recipient. Most recurrences appear within the first two to three years.
Seek review promptly if
- A firm lump with a crusted or ulcerated surface grows, bleeds or becomes painful.
- You notice a new lump in the neck, armpit or groin, or swelling in a limb, after any skin cancer.
- You take immunosuppressant medication and a lesion appears, changes, or does not heal.
Frequently asked questions
Which features make a squamous cell carcinoma higher risk?
A diameter above roughly two centimetres, invasion beyond the dermis into subcutaneous fat or deeper, perineural invasion, poor differentiation and certain aggressive subtypes all raise concern. Site matters too, since tumours of the lip, ear and temple have a higher rate of spread.
Should someone who has had a transplant stop immunosuppressant medication because of skin cancer risk?
No. That medication protects the transplant. The appropriate response is regular examination, early treatment of lesions, and joint review by the skin team and the transplant team, because adjustments to immunosuppression can measurably reduce the rate of new tumours.
What does surveillance after treatment look for?
Three things: recurrence at the treated site, new primary tumours elsewhere on the skin, and nodal spread in higher-risk cases. Review intervals are set by risk, and most recurrences appear within the first two to three years.
Risks & Limitations
- Incomplete excision, which may require a further operation to achieve clear margins.
- Recurrence of the skin cancer, and the need for surveillance for years afterwards.
- Scars are permanent. They mature and fade but never disappear.
- Problems with a graft or flap, including partial or complete loss, which may need further surgery.
- Numbness, altered sensation or nerve injury around the operated area.
- Melanoma carries a risk of spread that surgery cannot remove, even when the excision is complete.
- Pigment change, contour irregularity, or a scar that widens or thickens.
- Final assessment of the scar is made at 6–12 months, and surveillance continues longer.
When to Seek Care
- A lesion that changes in size, shape, colour or height, or that starts to bleed or itch.
- A new, rapidly growing nodule, or a sore that is not healing.
- A mole that becomes painful or bleeds.
- Swelling in a lymph node region — the neck, armpit or groin.
- A graft or flap that turns dark, cold or black, or a wound that opens or discharges.
- Fever above 38 °C, or spreading redness, warmth or pain around a wound.
References & Further Reading
- American Academy of Dermatology (AAD) — skin cancer diagnosis and treatment guidance
- American Cancer Society (ACS) — skin cancer types, staging and outlook
- Skin Cancer Foundation — prevention and skin self-examination resources
- American Society of Plastic Surgeons (ASPS) — reconstruction after skin cancer excision
- Cochrane Library — systematic reviews in skin cancer treatment and prevention
- Chinese Medical Association — clinical guidance for skin tumours and dermatologic surgery
This page is patient education, not medical advice, and it does not cite individual studies. Discuss your own case with a qualified clinician. To arrange an assessment at Chongqing West District Hospital, see Contact & Consultation.